Skip to main content

Table 4 Logistic regression analysis using AAA-1, ALP or FLI as predictor of a high FRS

From: Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study

FRS ≥ 20%

Univariate analysis

Multivariate analysis

Multivariate analysis

Predictor

OR

95% CI

P-value

OR

95% CI

P-value

OR

95% CI

P-value

PREVEND subjects (n = 312)

 AAA-1 positivity

0.79

0.47–1.33

0.395

1.03

0.57–1.85

0.922

–

–

–

 AAA-1 continuous

2.11

0.84–5.30

0.113

–

–

–

1.85

0.64–5.3

0.252

 ALP

1.04

1.02–1.06

 < 0.001

1.03

1.01–1.05

0.001

1.03

1.01–1.05

0.001

 FLI

1.02

1.01–1.03

 < 0.001

1.02

1.01–1.03

 < 0.001

1.02

1.01–1.03

 < 0.001

FLI ≥ 60 PREVEND subjects (n = 112)

 AAA-1 positivity

2.44

1.07–5.60

0.032

1.70

0.69–4.21

0.235

–

–

–

 AAA-1 continuous

7.80

0.96–63.19

0.051

–

–

–

3.90

0.41–37.8

0.235

 ALP

1.03

1.0–1.05

0.022

1.02

0.99–1.05

0.117

1.02

0.99–1.05

0.135

 FLI

1.06

1.02–1.1

0.001

1.05

1.01–1.09

0.004

1.05

1.01–1.09

0.003

FLI < 60 PREVEND subjects (n = 200)

 AAA-1 positivity

1.21

0.56–2.68

0.591

0.72

0.31–1.67

0.442

–

–

–

 AAA-1 continuous

2.12

0.7–6.4

0.185

–

–

–

1.60

0.46–5.5

0.455

 ALP

1.05

1.02–1.08

 < 0.001

1.04

1.02–1.07

0.001

1.04

1.02–1.07

0.001

 FLI

1.02

1–1.04

0.028

1.01

0.99–1.03

0.229

1.01

0.98–1.03

0.306

  1. FRS Framingham risk score, OR odds ratio, CI confidence interval, AAA-1 anti-apolipoprotein A-1 IgG, ALP alkaline phosphatase, FLI fatty liver index
  2. In multivariate analysis, only the indicated predictors were included in the model